Has Neuralink publicly tested neural implants for bladder control in humans?

Checked on December 11, 2025
Disclaimer: Factually can make mistakes. Please verify important information or breaking news. Learn more.

This fact-check may be outdated. Consider refreshing it to get the most current information.

Executive summary

Neuralink has announced and begun first‑in‑human trials (the PRIME study/CAN‑PRIME) and reported implants in people for motor and speech‑related uses, but available sources do not describe any publicly reported human implants specifically targeting bladder control as of the cited reporting (Neuralink trial openings and clinical updates; press summaries) [1] [2] [3].

1. Neuralink’s human trials are real and expanding — but focused on mobility and communication

Neuralink opened recruitment for its first‑in‑human trial in 2024 and has framed its clinical program around restoring autonomy to people with paralysis and enabling control of external devices (the PRIME study and related trial listings) [1] [4]. Independent reporting and company updates emphasize demonstrations where participants controlled cursors, robotic limbs and communicative interfaces — use cases tied to motor function and speech restoration rather than autonomic functions like bladder control [2] [3].

2. Company milestones have been publicized, but details on specific therapeutic targets are limited

Neuralink and media reports describe milestones — multiple implants in 2024–25 and plans to scale to dozens of participants in 2025 — but public descriptions center on general goals (motor control, restoring communication, projects like “Blindsight” for vision) rather than a program openly billed as a bladder‑control trial [5] [2] [6]. Neuralink’s own updates invite would‑be participants to learn about clinical trials, but they do not list bladder control as a named indication in the sources provided [7] [1].

3. No source in the provided set documents human bladder‑control implants by Neuralink

Search results include trial pages, company updates and wide‑ranging press coverage; none of those sources describe a human implant explicitly for bladder control. Available sources do not mention Neuralink having publicly tested neural implants in humans for bladder control [1] [2] [3].

4. What the public record does show about clinical scope and geography

Reporting and company materials show the trials began in the U.S. and have plans or approvals to expand internationally (Canada and other countries are mentioned in later reporting), with trial registrations and press summaries describing specific study names and growth targets — but again, the extant accounts emphasize motor and sensory restoration, not autonomic system control such as bladder function [2] [3] [8].

5. Why bladder control would be a different technical and regulatory problem

Bladder control involves autonomic and spinal circuits distinct from the cortical motor and sensory targets Neuralink has publicly prioritized. The cited reporting highlights work on cortical interfaces for motor/sensory/vision tasks and the stepwise nature of safety and efficacy testing in early human trials; the sources imply Neuralink’s immediate trial goals focus on restorations that map more directly onto cortical activity [2] [3]. The provided files do not discuss Neuralink pursuing autonomic endpoints such as micturition control in humans.

6. Alternate perspectives and limitations of public reporting

Neuralink’s own updates and media coverage (including tech outlets and IEEE analysis) present competing tones: company optimism about rapid progress and regulators’ cautious stepwise permissions. Some outlets celebrate fast clinical growth and user achievements, while watchdog groups and past reporting about animal studies raise concerns about safety and methods — both perspectives appear in the record supplied [2] [9] [10]. Importantly, the sources you provided do not include exhaustive trial protocols or all regulatory filings; absence of a mention in these sources is not proof Neuralink has not explored bladder control in internal or unpublished work — it only means it is not documented in the supplied reporting [1] [2].

7. Bottom line for the question asked

Based on the supplied sources, Neuralink has publicly implanted devices in human trial participants and promoted functional gains in motor and communication tasks, but none of the provided materials report that Neuralink has publicly tested neural implants in humans specifically for bladder control; available sources do not mention human bladder‑control implants by Neuralink [1] [2] [3].

If you want, I can search for trial registry entries, peer‑reviewed protocols, or regulatory filings that might list specific endpoints like bladder function and cite them directly.

Want to dive deeper?
Has Neuralink reported any human trials targeting bladder dysfunction?
What regulatory approvals has Neuralink received for human implant studies?
Have other companies tested neural implants for bladder control in humans?
What are the risks and ethical concerns of implanting electrodes for bladder control?
Are there published clinical results on neuroprosthetics restoring bladder function?